Enanta Pharmaceuticals Inc (ENTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $320.09M
Last updated: Nov 17, 2026 at 11:05 AM ET
Enanta Pharmaceuticals Inc (ENTA) Valuation Multiples
Enanta Pharmaceuticals (ENTA) trades at 4.8x sales and 3.1x book value. Its P/S of 4.8x is above its 5-year median of 4.7x. Its forward P/E is 44.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 44.0x |
| Price to sales | 4.8x |
| Price to book | 3.1x |
| PEG | N/A |
| FCF yield | -11.9% |
Historical Medians
Against its 10-year medians, its P/S is 32.4% below 7.1x and its P/B is 10.7% above 2.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 4.8x | 4.7x | 7.1x |
| P/B | 3.1x | 2.8x | 2.8x |
Valuation History
Over the 3 of the 10 year ends shown that have a P/E, its P/E ranged from 17.2x in 2018 to 38.1x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $15.77 | N/A | 5.4x | 3.6x |
| 2024 | $5.75 | N/A | 1.8x | 1.1x |
| 2023 | $9.41 | N/A | 2.7x | 1.8x |
| 2022 | $46.52 | N/A | 11.7x | 3.2x |
| 2021 | $74.78 | N/A | 16.3x | 4.0x |
| 2020 | $42.10 | N/A | 8.3x | 1.9x |
| 2019 | $61.78 | 38.1x | 6.6x | 2.5x |
| 2018 | $70.83 | 17.2x | 5.9x | 3.2x |
| 2017 | $58.68 | 38.1x | 8.7x | 3.5x |
| 2016 | $33.50 | N/A | 12.7x | 2.4x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ENTA
What is ENTA's forward P/E ratio?
Enanta Pharmaceuticals has a forward P/E ratio of 44.0x.
Is ENTA stock overvalued?
GNG's valuation label for ENTA is Fairly valued.
What is ENTA's price to sales ratio?
Enanta Pharmaceuticals has a price to sales ratio of 4.8x.
ENTA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors